Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 26, Issue 43, Pages 5584-5590Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612826666200813134328
Keywords
Subclinical Cushing's syndrome; adrenal incidentaloma; possible autonomous cortisol secretion; mild autonomous cortisol secretion; mild autonomous cortisol excess; adrenal tumor; non-functional adrenal incidentaloma
Categories
Funding
- Ministry of Science, Republic of Serbia [175067]
Ask authors/readers for more resources
A growing number of patients with adrenal incidentalomas and subclinical Cushing's syndrome (SCS) led to an increasing number of different guidelines, and diagnostic and treatment recommendations. Excess cortisol secretion in patients with SCS is associated with several comorbidities, such as hypertension, dyslipidemia, type 2 diabetes mellitus, and obesity, which in the long-term increase mortality of these patients. Subtle cortisol secretion affects bone health, quality of life and causes depression, but due to the unapparent clinical features, patients with SCS are often at risk between over and under treatment. This narrative review aimed to summarize the latest recommendations on the approach to the patient with subclinical Cushing's syndrome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available